Detalhe da pesquisa
1.
Chronic intestinal failure: an overview and future perspectives.
Rev Esp Enferm Dig
; 114(5): 251-253, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35373575
2.
Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury.
Rev Esp Enferm Dig
; 114(6): 356-357, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35073724
3.
Safety of propofol sedation directed by endoscopists: how long should we continue to generate evidence?
Rev Esp Enferm Dig
; 110: 260, 2018 03 26.
Artigo
Inglês
| MEDLINE | ID: mdl-29578349
4.
The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU.
Inflamm Bowel Dis
; 2024 Mar 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38518109
5.
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
J Crohns Colitis
; 17(1): 83-91, 2023 Jan 27.
Artigo
Inglês
| MEDLINE | ID: mdl-35913456
6.
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).
J Clin Med
; 11(24)2022 Dec 19.
Artigo
Inglês
| MEDLINE | ID: mdl-36556155
7.
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
J Clin Med
; 11(2)2022 Jan 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35054116
8.
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab.
J Clin Med
; 11(15)2022 Aug 03.
Artigo
Inglês
| MEDLINE | ID: mdl-35956133
9.
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
Inflamm Bowel Dis
; 28(11): 1725-1736, 2022 11 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35166347
10.
Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.
Gastroenterol Hepatol
; 34(7): 443-8, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-21724297
11.
Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach.
World J Gastroenterol
; 27(41): 7113-7124, 2021 Nov 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34887631
12.
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
Inflamm Bowel Dis
; 26(4): 606-616, 2020 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-31504569
13.
Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
J Clin Gastroenterol
; 43(10): 950-6, 2009.
Artigo
Inglês
| MEDLINE | ID: mdl-19448569
14.
Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
Curr Med Res Opin
; 35(7): 1297-1304, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30722703
15.
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial.
Dig Liver Dis
; 51(4): 529-535, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30712954
16.
Infliximab-related hepatitis: a case study and literature review.
Dig Dis Sci
; 58(11): 3362-7, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-23645381
17.
Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response.
Hepatogastroenterology
; 55(86-87): 1609-14, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-19102352
18.
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
Gastroenterol Hepatol
; 31(7): 421-6, 2008.
Artigo
Inglês
| MEDLINE | ID: mdl-18783686
19.
Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.
J Crohns Colitis
; 12(11): 1270-1279, 2018 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-30052856
20.
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
Inflamm Bowel Dis
; 23(8): 1394-1402, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28671873